In the 1990s, a randomized trial was designed to determine the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) during chemoradiotherapy in patients with limited-stage small-cell lung cancer [18]. This evidence concerns the gene CSF2 and small cell lung carcinoma.